author-photo

Francois Ringeisen

Novartis

20

Papers

673

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Abstract PS12-13: Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Final analysis from the Phase 1 single arm trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1

2017 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2 − advanced breast cancer: results from BOLERO-2

2017 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (77)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (245)
Abstract P2-11-08: Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Correlation of PIK3CA mutations in cell-free DNA (cfDNA) and efficacy of everolimus (EVE) in metastatic breast cancer: Results from BOLERO-2.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (9)
PO56 BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR–POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HER2–) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC)

2015 The Breast
Show All
- Source
- Cite
- Save
Citations (0)